CMV Reactivation After Allogeneic HCT and Relapse Risk: Evidence for Early Protection in Acute Myeloid Leukemia

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2013 Jun 8

PMID 23744585

Citations 145

Authors

Margaret L Green

Wendy M Leisenring

Hu Xie

Roland B Walter

Marco Mielcarek

Brenda M Sandmaier

Stanley R Riddell

Michael Boeckh

Affiliations

Soon will be listed here.

Abstract

The association between cytomegalovirus (CMV) reactivation and relapse was evaluated in a large cohort of patients with acute myeloid leukemia (AML) (n = 761), acute lymphoblastic leukemia (ALL) (n = 322), chronic myeloid leukemia (CML) (n = 646), lymphoma (n = 254), and myelodysplastic syndrome (MDS) (n = 371) who underwent allogeneic hematopoietic cell transplantation (HCT) between 1995 and 2005. In multivariable models, CMV pp65 antigenemia was associated with a decreased risk of relapse by day 100 among patients with AML (hazard ratio [HR] = 0.56; 95% confidence interval [CI], 0.3-0.9) but not in patients with ALL, lymphoma, CML, or MDS. The effect appeared to be independent of CMV viral load, acute graft-versus-host disease, or ganciclovir-associated neutropenia. At 1 year after HCT, early CMV reactivation was associated with reduced risk of relapse in all patients, but this did not reach significance for any disease subgroup. Furthermore, CMV reactivation was associated with increased nonrelapse mortality (HR = 1.31; 95% CI, 1.1-1.6) and no difference in overall mortality (HR = 1.05; 95% CI, 0.9-1.3). This report demonstrates a modest reduction in early relapse risk after HCT associated with CMV reactivation in a large cohort of patients without a benefit in overall survival.

Citing Articles

Pneumonia in Transplant Recipients: A Comprehensive Review of Diagnosis and Management.

Pata R, Kristeva J, Kosuru B Cureus. 2024; 16(11):e73669.

PMID: 39544950 PMC: 11562015. DOI: 10.7759/cureus.73669.

Association between early anti-cytomegalovirus therapy and the incidence of chronic graft-versus-host disease.

Miyao K, Murata M, Nishida T, Ozawa Y, Uchida N, Fukuda T Int J Hematol. 2024; 121(1):110-125.

PMID: 39543007 DOI: 10.1007/s12185-024-03871-4.

The BIM deletion polymorphism potentiates the survival of leukemia stem and progenitor cells and impairs response to targeted therapies.

Yu M, Nah G, Krishnan V, Sulaimi F, Ng K, Wang C Leukemia. 2024; 39(1):134-143.

PMID: 39438588 DOI: 10.1038/s41375-024-02418-0.

Insights into cytomegalovirus-associated T cell receptors in recipients following allogeneic hematopoietic stem cell transplantation.

Xia J, Xiao Y, Gui G, Gong S, Wang H, Li X Virol J. 2024; 21(1):236.

PMID: 39350155 PMC: 11443867. DOI: 10.1186/s12985-024-02511-x.

Risk and impact of cytomegalovirus infection in lymphoma patients treated with bendamustine.

Huang J, Yeh C, Gong Y, Tsai M, Lin Y, Tsai C Ann Hematol. 2024; 103(10):4099-4109.

PMID: 39158713 DOI: 10.1007/s00277-024-05839-0.

References

Nachbaur D, Clausen J, Kircher B . Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants. Eur J Haematol. 2006; 76(5):414-9. DOI: 10.1111/j.1600-0609.2005.00625.x. View

Challa-Malladi M, Lieu Y, Califano O, Holmes A, Bhagat G, Murty V . Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell. 2011; 20(6):728-40. PMC: 3660995. DOI: 10.1016/j.ccr.2011.11.006. View

Green M, Leisenring W, Stachel D, Pergam S, Sandmaier B, Wald A . Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012; 18(11):1687-99. PMC: 3467354. DOI: 10.1016/j.bbmt.2012.05.015. View

Kollman C, HOWE C, Anasetti C, Antin J, Davies S, Filipovich A . Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001; 98(7):2043-51. DOI: 10.1182/blood.v98.7.2043. View

Elmaagacli A, Steckel N, Koldehoff M, Hegerfeldt Y, Trenschel R, Ditschkowski M . Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood. 2011; 118(5):1402-12. DOI: 10.1182/blood-2010-08-304121. View

Ito S, Pophali P, CO W, Koklanaris E, Superata J, Fahle G . CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML. Bone Marrow Transplant. 2013; 48(10):1313-6. PMC: 5274543. DOI: 10.1038/bmt.2013.49. View

Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C . Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood. 2003; 102(13):4255-60. DOI: 10.1182/blood-2002-10-3263. View

Grimwade D, Hills R, Moorman A, Walker H, Chatters S, Goldstone A . Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116(3):354-65. DOI: 10.1182/blood-2009-11-254441. View

Charoudeh H, Terszowski G, Czaja K, Gonzalez A, Schmitter K, Stern M . Modulation of the natural killer cell KIR repertoire by cytomegalovirus infection. Eur J Immunol. 2012; 43(2):480-7. DOI: 10.1002/eji.201242389. View

10.

George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I . Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis. 2010; 12(4):322-9. DOI: 10.1111/j.1399-3062.2010.00504.x. View

11.

Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M . The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia. 2009; 23(6):1131-8. DOI: 10.1038/leu.2009.1. View

12.

Erard V, Guthrie K, Riddell S, Boeckh M . Impact of HLA A2 and cytomegalovirus serostatus on outcomes in patients with leukemia following matched-sibling myeloablative allogeneic hematopoietic cell transplantation. Haematologica. 2006; 91(10):1377-83. View

13.

Remberger M, Ringden O . Survival after bone-marrow transplantation. Lancet. 2002; 359(9309):888. DOI: 10.1016/S0140-6736(02)07926-6. View

14.

Della Chiesa M, Falco M, Podesta M, Locatelli F, Moretta L, Frassoni F . Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus?. Blood. 2011; 119(2):399-410. DOI: 10.1182/blood-2011-08-372003. View

15.

Przepiorka D, Weisdorf D, MARTIN P, Klingemann H, Beatty P, Hows J . 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15(6):825-8. View

16.

Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik W, Tosti A . Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002; 295(5562):2097-100. DOI: 10.1126/science.1068440. View

17.

Boeckh M, Gooley T, Myerson D, Cunningham T, Schoch G, Bowden R . Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996; 88(10):4063-71. View

18.

Thomson K, Mackinnon S, Peggs K . CMV-specific cellular therapy for acute myeloid leukemia?. Blood. 2012; 119(4):1088-90. DOI: 10.1182/blood-2011-10-383943. View

19.

Beziat V, Liu L, Malmberg J, Ivarsson M, Sohlberg E, Bjorklund A . NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood. 2013; 121(14):2678-88. PMC: 3617633. DOI: 10.1182/blood-2012-10-459545. View

20.

Boeckh M, Bowden R, Gooley T, Myerson D, Corey L . Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood. 1999; 93(5):1781-2. View